ClinicalTrials.Veeva
Menu

Find clinical trials for Heart Disease in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Heart Diseases
Coronary Artery Disease
Cardiovascular Diseases
Myocardial Ischemia
Heart Failure
Coronary Disease
Hypertension

Heart Disease trials near Sevilla, AN, ESP:

Locations recently updated

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (Re-PHIRE)

is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart...

Enrolling
Heart Failure
Pulmonary Hypertension (World Health Organization Group 2)
Drug: AZD3427
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Sevilla, Spain and 63 other locations

tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease...

Enrolling
Ischemic Heart Disease
Coronary Artery Disease
Other: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Fundación EPIC

Sevilla, Spain and 42 other locations

Evaluation of TAVR using the NAVITOR valve in a Global Investigation.

Enrolling
Symptomatic Severe Aortic Stenosis
Device: Navitor Transcatheter Aortic Valve and FlexNav Delivery System
Abbott
Abbott

Sevilla, Spain and 37 other locations

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

Phase 3

Novo Nordisk
Novo Nordisk

Sevilla, Spain and 468 other locations

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardio...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

Phase 3

Novo Nordisk
Novo Nordisk

Sevilla, Spain and 553 other locations

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

Phase 3

Amgen
Amgen

Sevilla, Andalucía, Spain and 851 other locations

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Sevilla, Spain and 177 other locations

of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) ...

Enrolling
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
Allogeneic Hematopoietic Cell Transplant
Biological: tabelecleucel

Phase 3

Atara Biotherapeutics

Sevilla, Spain and 70 other locations

Locations recently updated

of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease...

Enrolling
Chronic Kidney Disease
Type 1 Diabetes Mellitus
Other: Placebo
Drug: Finerenone

Phase 3

Bayer
Bayer

Castilleja de la Cuesta, Spain and 80 other locations

) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputatio...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: MK-0616

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Sevilla, Andalucia, Spain and 451 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems